healthcare
healthcare Articles
Akorn shares were crushed early on Monday after a Delaware judge ruled that German health care group Fresenius could walk away from its $4.75 billion merger deal.
Published:
Last Updated:
Here is a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of October.
Published:
Last Updated:
Biotechnology company Equillium has amended its filing with the SEC regarding its initial public offering.
Published:
Last Updated:
GW Pharmaceuticals shares made a solid gain on Thursday after it received a critical update from the DEA.
Published:
Last Updated:
Protagonist Therapeutics shares made a solid gain on Thursday after the company announced a key update from the FDA.
Published:
Last Updated:
Geron shares were absolutely crushed on Thursday morning after it was announced that Janssen Biotech has terminated the 2014 collaboration and license agreement with the firm.
Published:
Last Updated:
Tilray shares got a little higher on Wednesday after the company announced that it had entered into a supply agreement with 7ACRES, a subsidiary of Supreme Cannabis.
Published:
Last Updated:
Verastem shares saw a handy gain on Wednesday after the company set an exclusive licensing agreement to develop and commercialize Copiktra.
Published:
Last Updated:
The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
The September 14 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
Akcea and Ionis Pharmaceuticals shares made a solid gain on Monday after the companies announced positive top-line data for a midstage trial in patients with established cardiovascular disease and...
Published:
Last Updated:
Clinical-stage biopharmaceutical company Kodiak Sciences expects to price 9 million shares for an initial public company valued up to more than $155 million.
Published:
Last Updated:
Amarin shares absolutely skyrocketed on Monday after the company announced topline results from the Vascepa cardiovascular (CV) outcomes trial, REDUCE-IT. Needless to say, the results were very...
Published:
Last Updated:
Changing U.S. demographics will change the proportion of Americans who suffer from Alzheimer's and other dementia-related diseases. The diseases are forecast to hit Hispanics and African Americans...
Published:
Last Updated:
Cannabis stocks had a huge showing on Wall Street this past week. In fact, most of the news flow was surrounding these stocks and how investors were pouring money into them.
Published:
Last Updated: